AQR Capital Management
CERE

AQR Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

AQR Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,816
Closed -$810K – 2908
2024
Q2 		$810K Buy
19,816
+71
+0.4% +$2.96K ﹤0.01% 1846
2024
Q1 		$835K Buy
19,745
+167
+0.9% +$7.01K ﹤0.01% 1770
2023
Q4 		$830K Buy
+19,578
New +$563K ﹤0.01% 1670
2023
Q3 		– Sell
-7,021
Closed -$223K – 2403
2023
Q2 		$223K Sell
7,021
-6,630
-49% -$203K ﹤0.01% 2054
2023
Q1 		$333K Sell
13,651
-2,754
-17% -$80.8K ﹤0.01% 1915
2022
Q4 		$517K Sell
16,405
-7,485
-31% -$211K ﹤0.01% 1803
2022
Q3 		$675K Buy
23,890
+1,237
+5% +$36.8K ﹤0.01% 1669
2022
Q2 		$599K Buy
22,653
+13,363
+144% +$379K ﹤0.01% 1622
2022
Q1 		$325K Buy
+9,290
New +$271K ﹤0.01% 1946

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

AQR Capital Management's CERE Position: Q3 2024 in Review

AQR Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 19,816 shares — an estimated $810K sold.

AQR Capital Management first reported a position in CERE in Q1 2022 and held it in 9 quarters. The position peaked at $835K in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • AQR Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • AQR Capital Management sold 19,816 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $810K.
  • AQR Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 9 quarters.
  • AQR Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $835K in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on AQR Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.